Alcon

Alcon has acquired Neurotech Pharmaceuticals for $550 million and may make additional success‑based payments. The deal adds Encelto to its retina portfolio — the only therapy approved in the U.S. for MacTel type 2 — addressing around 25,000 diagnosed patients in the U.S. Neurotech brings encapsulated cell therapies for chronic and neurodegenerative eye diseases. Alcon expects slight revenue growth in 2027 and a temporary hit to adjusted earnings per share, after which the acquisition is expected to be accretive. » Więcej na finanzen.net

Alcon has introduced the modular surgical microscope “Unity M” for eye surgery, which is said to provide a more stable view through an improved red reflex zone and adjustable color illumination. The device is approved in the US, Japan, Canada, India and Europe; deliveries began in September with the market launch first in the US and Japan, and later in Europe. The stock reacted with an intraday decline of around 1 percent. » Więcej na finanzen.net

Alcon, through its subsidiary Alcon Finance Corporation, is issuing a five‑year €500 million bond with a 3.875% coupon. The bond will be listed on the Luxembourg Stock Exchange and traded on the Euro MTF; closing of the transaction is scheduled for 2 September. Proceeds are to be used for general corporate purposes, including wholly or partly refinancing existing debt. » Więcej na finanzen.net

Alcon announced the placement of a senior bond of €500 million maturing in 2033 with a coupon of 3.875%. The bonds are being issued by Alcon Finance Corporation and are secured by a senior guarantee from Alcon Inc. An admission to trading on the Luxembourg Stock Exchange and on the Euro MTF has been applied for; the closing of the issue is scheduled for 2 September 2026. Proceeds will be used for general corporate purposes, including possible refinancing of existing debt. » Więcej na de.investing.com

Sustainable Growth Advisers (SGA) exited its position in Alcon, citing subdued cataract and contact lens markets and rising competition in premium intraocular lenses that is eroding Alcon’s market share. Despite Alcon’s 6% constant-currency revenue growth and 16%+ EPS growth in Q1 and strong product launches, SGA gradually reduced the holding and redeployed capital into Schneider Electric to pursue higher growth. SGA views Alcon as a market leader but trimmed exposure due to near-term demand pressures and increased competitive risk. » Więcej na finance.yahoo.com